Hartmut Döhner Selected Research

Biomarkers (Surrogate Marker)

1/2019	Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia.
12/2016	All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study.
7/2014	Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia.
4/2012	Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33.
1/2010	Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia.
11/2008	First demonstration of leukemia imaging with the proliferation marker 18F-fluorodeoxythymidine.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hartmut Döhner Research Topics

Disease

116	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2024 - 07/2003
61	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2023 - 08/2002
50	Neoplasms (Cancer) 01/2023 - 09/2002
44	Leukemia 11/2023 - 04/2002
13	Infections 11/2023 - 04/2005
11	Disease Progression 11/2020 - 11/2002
10	Neutropenia 02/2024 - 04/2005
10	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 07/2023 - 05/2006
10	Residual Neoplasm 01/2023 - 10/2004
9	Hematologic Neoplasms (Hematological Malignancy) 03/2024 - 04/2005
7	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 11/2007 - 09/2002
6	Chromosome Aberrations (Chromosome Abnormalities) 01/2020 - 01/2004
6	Acute Promyelocytic Leukemia 11/2019 - 02/2009
5	Febrile Neutropenia 12/2023 - 01/2020
4	Thrombocytopenia (Thrombopenia) 02/2024 - 01/2020
4	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2023 - 09/2006
4	Multiple Myeloma 01/2022 - 07/2003
4	Lymphoma (Lymphomas) 02/2021 - 03/2003
4	Carcinogenesis 01/2017 - 01/2013
4	Melanoma (Melanoma, Malignant) 05/2013 - 09/2002
4	Hodgkin Disease (Hodgkin's Disease) 05/2012 - 04/2006
3	Pneumonia (Pneumonitis) 12/2023 - 11/2021
3	Pathologic Complete Response 07/2023 - 12/2005
3	Hemorrhage 01/2022 - 02/2009
3	Lymphadenopathy 05/2008 - 08/2004
3	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 07/2007 - 08/2004
3	Breast Neoplasms (Breast Cancer) 03/2007 - 09/2002
2	Thrombotic Microangiopathies 03/2024 - 12/2017
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 07/2023 - 02/2006
2	Sepsis (Septicemia) 07/2023 - 04/2005
2	COVID-19 01/2023 - 01/2022
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2021 - 01/2013
2	Trisomy (Trisomies) 01/2020 - 01/2004

Drug/Important Bio-Agent (IBA)

18	Azacitidine (5 Azacytidine)FDA Link 02/2024 - 07/2015
16	fludarabineIBA 01/2022 - 08/2004
15	Rituximab (Mabthera)FDA Link 01/2022 - 09/2011
15	Proteins (Proteins, Gene)FDA Link 01/2021 - 12/2005
15	AntigensIBA 01/2019 - 09/2002
11	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2023 - 01/2009
11	DNA (Deoxyribonucleic Acid)IBA 11/2022 - 03/2003
11	NucleophosminIBA 01/2019 - 12/2005
10	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 02/2006
10	MicroRNAs (MicroRNA)IBA 01/2020 - 02/2011
8	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2024 - 03/2007
8	midostaurinIBA 01/2022 - 01/2017
8	Core Binding Factors (Core-Binding Factor)IBA 12/2020 - 08/2007
7	venetoclaxIBA 02/2024 - 03/2014
7	Messenger RNA (mRNA)IBA 04/2013 - 09/2002
6	Decitabine FDA Link 12/2023 - 03/2012
6	Biomarkers (Surrogate Marker)IBA 01/2019 - 11/2008
5	Lenalidomide (CC 5013)FDA Link 01/2022 - 03/2013
5	Transcription Factors (Transcription Factor)IBA 01/2021 - 04/2005
5	Immunoglobulins (Immunoglobulin)IBA 11/2020 - 08/2002
4	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 12/2023 - 08/2010
4	Gemtuzumab (Mylotarg)FDA Link 07/2023 - 01/2016
4	obinutuzumabIBA 01/2023 - 03/2014
4	Phosphotransferases (Kinase)IBA 01/2022 - 03/2013
4	EnzymesIBA 01/2021 - 08/2005
4	Bendamustine Hydrochloride FDA Link 02/2020 - 09/2011
4	Arsenic Trioxide (Trisenox)FDA Link 11/2019 - 02/2009
4	Peptides (Polypeptides)IBA 01/2014 - 08/2005
4	Alemtuzumab (Campath)FDA Link 08/2013 - 09/2006
4	CCAAT-Enhancer-Binding Protein-alphaIBA 02/2011 - 02/2004
4	Imatinib Mesylate (Gleevec)FDA Link 11/2007 - 12/2006
4	Hyaluronic Acid (Hyaluronan)IBA 06/2007 - 09/2002
3	enasidenibIBA 12/2023 - 01/2021
3	ibrutinibIBA 01/2023 - 01/2018
3	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 01/2022 - 02/2006
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2022 - 05/2008
3	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2021
3	ivosidenibIBA 01/2022 - 01/2021
3	Protein Isoforms (Isoforms)IBA 01/2020 - 03/2013
3	Valproic Acid (Depakote)FDA LinkGeneric 01/2020 - 06/2014
3	Dasatinib (BMS 354825)FDA Link 01/2018 - 10/2008
3	Chlorambucil (Leukeran)FDA Link 06/2014 - 10/2009
3	NF-kappa B (NF-kB)IBA 04/2013 - 11/2002
2	guadecitabineIBA 01/2024 - 12/2023
2	palbociclibIBA 05/2023 - 01/2022
2	InterferonsIBA 01/2023 - 01/2014
2	VaccinesIBA 01/2023 - 08/2005
2	Immunomodulating AgentsIBA 01/2022 - 01/2017
2	Hydroxyurea (Hydrea)FDA LinkGeneric 12/2021 - 01/2021
2	BI 6727IBA 08/2021 - 08/2014
2	Circular RNAIBA 01/2021 - 12/2017
2	Monoclonal AntibodiesIBA 01/2021 - 02/2006
2	fms-Like Tyrosine Kinase 3IBA 10/2020 - 01/2020
2	Histone Deacetylase InhibitorsIBA 01/2020 - 07/2016
2	Thymidine KinaseIBA 01/2020 - 01/2018

Therapy/Procedure

55	Therapeutics 12/2023 - 09/2002
41	Drug Therapy (Chemotherapy) 02/2024 - 08/2002
29	Stem Cell Transplantation 03/2024 - 04/2002
11	Immunotherapy 04/2020 - 09/2002
10	Hematopoietic Stem Cell Transplantation 10/2022 - 12/2006
6	Transplantation 03/2024 - 01/2016
6	Induction Chemotherapy 12/2023 - 11/2005
5	Cell Transplantation 07/2023 - 02/2008
4	Salvage Therapy 11/2019 - 02/2009
2	Radioimmunotherapy 07/2023 - 04/2002
2	Precision Medicine 11/2022 - 03/2017
2	Aftercare (After-Treatment) 01/2020 - 01/2016